Targeting a specific immune checkpoint in melanoma treatment
Cell type-directed Tim-3 targeting in melanoma
This study is looking at how blocking a protein called Tim-3 can help your immune system fight melanoma better by boosting the activity of immune cells, and it aims to find out how this might improve treatment outcomes for people with this skin cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Brigham and Women's Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11083732 on NIH RePORTER |
What this research studies
This research investigates the role of Tim-3, an immune checkpoint, in enhancing the body's ability to fight melanoma. By blocking Tim-3, the study aims to rejuvenate T-cell immunity against tumors. The approach involves understanding how Tim-3 affects not only T-cells but also other immune cells like dendritic cells and macrophages, which may influence treatment outcomes. The research will utilize various models to explore the effects of Tim-3 targeting on tumor growth and immune response.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with metastatic melanoma who may benefit from enhanced immune therapies.
Not a fit: Patients with non-melanoma skin cancers or those who have not been diagnosed with cancer may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective melanoma treatments by improving the immune system's ability to combat cancer.
How similar studies have performed: Previous research has shown promising results with immune checkpoint inhibitors, suggesting that targeting Tim-3 could be a viable approach in cancer therapy.
Where this research is happening
Boston, United States
- Brigham and Women's Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Barthel, Steven Russell — Brigham and Women's Hospital
- Study coordinator: Barthel, Steven Russell
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.